Journal profile · Oncology
Seminars in Cancer Biology
ISSN 1044-579X · eISSN 1096-3650 · Academic Press Inc. · ENGLAND · Bimonthly · Founded 1990
Seminars in Cancer Biology: CAS Zone 2 · Medicine (2025 upgraded edition, Top journal); impact factor 20.12; hybrid open access; APC about USD 6,060; median 136 days to acceptance (79 articles, last 24 months); community-reported acceptance: fairly hard; 123 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Seminars in Cancer Biology is published by Academic Press Inc. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Cells and Metastasis, Epigenetics and DNA Methylation and Cancer Genomics and Diagnostics, together about 22.1% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Seminars in Cancer Biology (YSCBI) is a review journal dedicated to keeping scientists informed of developments in the field of molecular oncology. Each issue is thematic in approach, devoted to an important topic of interest to cancer biologists, from the underlying genetic and molecular causes of cellular transformation and cancer to the molecular basis of potential therapies. Every issue is edited by a guest editor or editors, an internationally acknowledged expert(s) in the field and contains approximately eight to twelve authoritative invited reviews on different aspects of the subject area. The aim of each issue is to provide a coordinated, readable, and lively review of a selected area.The journal publishes topics including:Role of glycation in different types of cancerImmuno-Oncological BiomarkersEpigenetics: solid tumors and haematological malignanciesCurrent Vision on target enzymes for cancer therapyTranslational Cancer GenomicsFOXO family in cancerEmerging trends in biomarker discovery: ease of prognosis and prediction in cancerSome chinks in Ras armor: novel cancer therapeutics on the horizonConference - Cancer Stem Cells: impact on treatment
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editorial board by country: none in mainland China; most named United States 5, Spain 3, Netherlands 3, United Kingdom 2, Sweden 1 (14 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Cells and MetastasisMedicine8%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology7.5%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology6.6%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5.7%
- Cancer Immunotherapy and BiomarkersMedicine5.5%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology5.4%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance4.8%
- Human auditory perception and evaluationEngineering4.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 20.12LetPub ·
- Impact factor (publisher)
- 20.3Publisher website ·
- CiteScore 2026-06
- 42LetPub ·
- CiteScore (publisher)
- 42Publisher website ·
- SJR 2026-06
- 4.91LetPub ·
- SNIP 2026-06
- 3.39LetPub ·
- h-index
- 134LetPub ·
- h-index
- 228OpenAlex ·
- i10-index
- 2,200OpenAlex ·
- 2-year mean citedness
- 11.01OpenAlex ·
- Self-citation rate
- 2.5%LetPub ·
- Share of gold OA articles
- 30.52%LetPub ·
Volume
- Articles per year
- 88LetPub ·
Articles by year OpenAlex count · 2,666 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 42 | 22 | 65 |
| 2025 | 123 | 37 | 996 |
| 2024 | 57 | 26 | 1,383 |
| 2023 | 99 | 46 | 5,055 |
| 2022 | 177 | 77 | 12,039 |
| 2021 | 240 | 117 | 14,974 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
136 daysMedian, submission to acceptance · P25–P75 92 days – 197 days
- Acceptance to online
- median 4 days (79 articles)
- Submission to online
- median 140 days
- Sample
- 79 articles with submission and acceptance dates (176 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly hardLetPub ·
- Submission to first decision
- 6 daysPublisher website ·
- First decision after review
- 50 daysPublisher website ·
- Submission to acceptance
- 117 daysPublisher website ·
- Acceptance to publication
- 4 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 6,060 / EUR 5,670 / GBP 4,850 / JPY 751,620 | — | — | |
| Publisher website | USD 5,930 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Templates
- LaTeX and Word
Article types accepted2
- invited review articlesSeminars in Cancer Biology publishes invited review articles only.Length not stated
- review articleSeminars in Cancer Biology publishes invited review articles only. Articles should be 7 to 8 printed pages in length (calculated at approximately 880 words per …Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Academic Press Inc.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1990
- ISSN
- 1044-579X
- Electronic ISSN
- 1096-3650
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Seminars in Cancer Biology
What CAS zone is Seminars in Cancer Biology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Seminars in Cancer Biology is in Zone 2 of Medicine, and in Zone 2 of the minor category Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Seminars in Cancer Biology?
The latest impact factor listed by LetPub is 20.12; CiteScore 42, h-index 228.
How long does peer review take at Seminars in Cancer Biology?
Based on the dates recorded on 79 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 136 days (interquartile range 92–197 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Seminars in Cancer Biology?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Templates: LaTeX and Word. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Seminars in Cancer Biology based?
Of the 14 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (5), Spain (3) and Netherlands (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Seminars in Cancer Biology?
According to LetPub and DOAJ records, Seminars in Cancer Biology is indexed in SCIE and Scopus.
Is Seminars in Cancer Biology open access, and what is the APC?
Seminars in Cancer Biology is a hybrid journal. For open-access publication: APC about USD 6,060.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .